• +1-646-491-9876
    • +91-20-67278686

    Search

    Women Infertility - Pipeline Review, H1 2017

    Women Infertility - Pipeline Review, H1 2017

    • Report Code ID: RW0001709457
    • Category Pharmaceuticals
    • No. of Pages 190
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Women Infertility - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H1 2017, provides an overview of the Women Infertility (Women's Health) pipeline landscape.

    Infertility is the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Treatment depends on the cause of infertility.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 14, 14, 1, 28, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

    Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health) .
    - The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 6
    List of Figures 7
    Introduction 8
    Publisher Report Coverage 8
    Women Infertility - Overview 9
    Women Infertility - Therapeutics Development 10
    Pipeline Overview 10
    Pipeline by Companies 11
    Pipeline by Universities/Institutes 15
    Products under Development by Companies 16
    Products under Development by Universities/Institutes 20
    Women Infertility - Therapeutics Assessment 21
    Assessment by Target 21
    Assessment by Mechanism of Action 24
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Women Infertility - Companies Involved in Therapeutics Development 31
    4P Therapeutics LLC 31
    AbbVie Inc 31
    Addex Therapeutics Ltd 32
    AlphaMab Co Ltd 32
    APAvadis Biotechnologies Srl 33
    ASKA Pharmaceutical Co Ltd 33
    Astellas Pharma Inc 34
    Bayer AG 34
    Dong-A Socio Holdings Co Ltd 35
    Dongkook Pharmaceutical Co Ltd 36
    ElexoPharm GmbH 36
    EndoCeutics Inc 37
    Enteris BioPharma Inc 37
    Evotec AG 38
    Ferring International Center SA 38
    Forendo Pharma Ltd 39
    Glycotope GmbH 39
    Isifer AB 40
    Kissei Pharmaceutical Co Ltd 40
    Lipicard Technologies Ltd 41
    Livzon Pharmaceutical Group Inc 41
    Luye Pharma Group Ltd 42
    Merck & Co Inc 42
    Navya Biologicals Pvt Ltd 43
    Nippon Shinyaku Co Ltd 43
    Nora Therapeutics Inc 44
    ObsEva SA 44
    Ogeda SA 45
    Orphagen Pharmaceuticals Inc 45
    Pangen Biotech Inc. 46
    Pantec Biosolutions AG 46
    PharmaEssentia Corp 47
    Philogen SpA 47
    Repros Therapeutics Inc 48
    Richter Gedeon Nyrt 48
    SK Chemicals Co Ltd 49
    Takeda Pharmaceutical Company Ltd 49
    TocopheRx Inc 50
    ValiRx Plc 50
    Viramal Ltd 51
    Zydus Cadila Healthcare Ltd 51
    Women Infertility - Drug Profiles 52
    acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 52
    ADX-68692 - Drug Profile 53
    AKP-501 - Drug Profile 54
    ASP-1707 - Drug Profile 55
    barusiban - Drug Profile 56
    BAY-1128688 - Drug Profile 57
    BAY-1158061 - Drug Profile 58
    Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile 59
    Biosimilar 5 for Infertility and Oncology - Drug Profile 60
    Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile 61
    Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology - Drug Profile 62
    choriogonadotropin alfa biosimilar - Drug Profile 63
    choriogonadotropin alfa biosimilar - Drug Profile 64
    danazol - Drug Profile 65
    Drug 1 for Endometriosis - Drug Profile 66
    Drug 2 for Endometriosis - Drug Profile 67
    Drug 3 for Endometriosis - Drug Profile 68
    Drug 4 for Endometriosis - Drug Profile 69
    Drug 5 for Endometriosis - Drug Profile 70
    Drug to Antagonize P2X3 for Endometriosis - Drug Profile 71
    Drug to Inhibit C-Jun for Endometriosis - Drug Profile 72
    Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health - Drug Profile 73
    Drugs for Endometriosis and Uterine Fibroids - Drug Profile 74
    EC-313 - Drug Profile 75
    elagolix sodium - Drug Profile 76
    EVE-104 - Drug Profile 81
    FE-999310 - Drug Profile 82
    fezolinetant - Drug Profile 83
    follicle stimulating hormone biosimilar - Drug Profile 86
    follitropin alfa biosimilar - Drug Profile 87
    follitropin alfa biosimilar - Drug Profile 89
    follitropin alfa biosimilar - Drug Profile 90
    follitropin delta - Drug Profile 91
    FP-5677 - Drug Profile 93
    FSH-GEX - Drug Profile 94
    goserelin biosimilar - Drug Profile 96
    goserelin ER - Drug Profile 97
    Isifera - Drug Profile 98
    kisspeptin-54 - Drug Profile 99
    KLH-2109 - Drug Profile 100
    KN-015 - Drug Profile 102
    leuprolide acetate - Drug Profile 103
    LM-001 - Drug Profile 104
    LM-002 - Drug Profile 105
    LT-6121 - Drug Profile 106
    menotropins - Drug Profile 107
    MIA-602 - Drug Profile 108
    MK-8389 - Drug Profile 109
    Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility - Drug Profile 110
    NAV-013 - Drug Profile 111
    NS-580 - Drug Profile 112
    NT-100 - Drug Profile 113
    OBE-001 - Drug Profile 115
    PEG-FSH - Drug Profile 118
    Peptide to Agonize FSH Receptor for Women Infertility - Drug Profile 119
    Peptides for Endometriosis and Hepatic Tumor - Drug Profile 120
    Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 121
    PGL-1001 - Drug Profile 122
    PGL-2001 - Drug Profile 123
    progesterone - Drug Profile 124
    Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile 125
    relugolix - Drug Profile 126
    SKI-2670 - Drug Profile 129
    Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile 130
    Small Molecules for Female Infertility - Drug Profile 131
    Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 132
    Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 133
    Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology - Drug Profile 134
    Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 135
    Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 136
    Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 137
    SR-16234 - Drug Profile 138
    STI-2833 - Drug Profile 139
    Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 140
    TAK-448 - Drug Profile 141
    telapristone acetate - Drug Profile 143
    Tetravil - Drug Profile 152
    TOP-001 - Drug Profile 154
    TOP-002 - Drug Profile 155
    triptorelin - Drug Profile 156
    triptorelin acetate ER - Drug Profile 157
    triptorelin biosimilar - Drug Profile 158
    VAL-201 - Drug Profile 159
    VAL-301 - Drug Profile 164
    vilaprisan - Drug Profile 165
    VPE-001 - Drug Profile 166
    VPEA-004 - Drug Profile 167
    Women Infertility - Dormant Projects 168
    Women Infertility - Discontinued Products 171
    Women Infertility - Product Development Milestones 172
    Featured News & Press Releases 172
    Appendix 183
    Methodology 183
    Coverage 183
    Secondary Research 183
    Primary Research 183
    Expert Panel Validation 183
    Contact Us 183
    Disclaimer 184

    List of Tables

    Number of Products under Development for Women Infertility, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Women Infertility - Pipeline by 4P Therapeutics LLC, H1 2017
    Women Infertility - Pipeline by AbbVie Inc, H1 2017
    Women Infertility - Pipeline by Addex Therapeutics Ltd, H1 2017
    Women Infertility - Pipeline by AlphaMab Co Ltd, H1 2017
    Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H1 2017
    Women Infertility - Pipeline by ASKA Pharmaceutical Co Ltd, H1 2017
    Women Infertility - Pipeline by Astellas Pharma Inc, H1 2017
    Women Infertility - Pipeline by Bayer AG, H1 2017
    Women Infertility - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
    Women Infertility - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
    Women Infertility - Pipeline by ElexoPharm GmbH, H1 2017
    Women Infertility - Pipeline by EndoCeutics Inc, H1 2017
    Women Infertility - Pipeline by Enteris BioPharma Inc, H1 2017
    Women Infertility - Pipeline by Evotec AG, H1 2017
    Women Infertility - Pipeline by Ferring International Center SA, H1 2017
    Women Infertility - Pipeline by Forendo Pharma Ltd, H1 2017
    Women Infertility - Pipeline by Glycotope GmbH, H1 2017
    Women Infertility - Pipeline by Isifer AB, H1 2017
    Women Infertility - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
    Women Infertility - Pipeline by Lipicard Technologies Ltd, H1 2017
    Women Infertility - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017
    Women Infertility - Pipeline by Luye Pharma Group Ltd, H1 2017
    Women Infertility - Pipeline by Merck & Co Inc, H1 2017
    Women Infertility - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
    Women Infertility - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
    Women Infertility - Pipeline by Nora Therapeutics Inc, H1 2017
    Women Infertility - Pipeline by ObsEva SA, H1 2017
    Women Infertility - Pipeline by Ogeda SA, H1 2017
    Women Infertility - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
    Women Infertility - Pipeline by Pangen Biotech Inc., H1 2017
    Women Infertility - Pipeline by Pantec Biosolutions AG, H1 2017
    Women Infertility - Pipeline by PharmaEssentia Corp, H1 2017
    Women Infertility - Pipeline by Philogen SpA, H1 2017
    Women Infertility - Pipeline by Repros Therapeutics Inc, H1 2017
    Women Infertility - Pipeline by Richter Gedeon Nyrt, H1 2017
    Women Infertility - Pipeline by SK Chemicals Co Ltd, H1 2017
    Women Infertility - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Women Infertility - Pipeline by TocopheRx Inc, H1 2017
    Women Infertility - Pipeline by ValiRx Plc, H1 2017
    Women Infertility - Pipeline by Viramal Ltd, H1 2017
    Women Infertility - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Women Infertility - Dormant Projects, H1 2017
    Women Infertility - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Women Infertility - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Women Infertility - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Women Infertility, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    4P Therapeutics LLC
    AbbVie Inc
    Addex Therapeutics Ltd
    AlphaMab Co Ltd
    APAvadis Biotechnologies Srl
    ASKA Pharmaceutical Co Ltd
    Astellas Pharma Inc
    Bayer AG
    Dong-A Socio Holdings Co Ltd
    Dongkook Pharmaceutical Co Ltd
    ElexoPharm GmbH
    EndoCeutics Inc
    Enteris BioPharma Inc
    Evotec AG
    Ferring International Center SA
    Forendo Pharma Ltd
    Glycotope GmbH
    Isifer AB
    Kissei Pharmaceutical Co Ltd
    Lipicard Technologies Ltd
    Livzon Pharmaceutical Group Inc
    Luye Pharma Group Ltd
    Merck & Co Inc
    Navya Biologicals Pvt Ltd
    Nippon Shinyaku Co Ltd
    Nora Therapeutics Inc
    ObsEva SA
    Ogeda SA
    Orphagen Pharmaceuticals Inc
    Pangen Biotech Inc.
    Pantec Biosolutions AG
    PharmaEssentia Corp
    Philogen SpA
    Repros Therapeutics Inc
    Richter Gedeon Nyrt
    SK Chemicals Co Ltd
    Takeda Pharmaceutical Company Ltd
    TocopheRx Inc
    ValiRx Plc
    Viramal Ltd
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//women-infertility-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//women-infertility-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//women-infertility-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments